Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysis
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review and meta-analysis of cohort studies of adults with NAFLD to evaluate the pooled incidence of adverse events. Results: 19,406 articles were screened, 409 full-text articles reviewed, and 79 eligible studies (1,377,466 persons) were included. Mean age was 51.47 years and body mass index 28.90 kg/m2. Baseline comorbidities included metabolic syndrome (41.73%), cardiovascular disease (CVD) (16.83%), cirrhosis (21.97%), and nonalcoholic steatohepatitis (NASH) (58.85%). Incidence rate per 1,000 person-years for mortality included: all-cause (14.6), CVD-related (4.53), non-liver cancer-related (4.53), and liver-related (3.10). Incidence for liver-related events included overall (24.3), fibrosis progression (49.0), cirrhosis (10.9), liver transplant (12.0), and hepatocellular carcinoma (HCC) (3.39). Incidence for non-liver events included metabolic syndrome (25.4), hypertension (25.8), dyslipidemia (26.4), diabetes (19.0), CVD (24.77), renal impairment (30.3), depression/anxiety (29.1), and non-liver cancer (10.5). Biopsy-proven NASH had higher incidence of HCC (P=0.043) compared to non-NASH. Higher rates of CVD and mortality were observed in North America and Europe, hypertension and non-liver cancer in North America, and HCC in Western Pacific/Southeast Asia (P<0.05). No significant differences were observed by sex. Time-period analyses showed decreasing rates of cardiovascular and non-liver cancer mortality and increasing rates of decompensated cirrhosis (P<0.05). Conclusions: People with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.
Abstract
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review and meta-analysis of cohort studies of adults with NAFLD to evaluate the pooled incidence of adverse events. Results: 19,406 articles were screened, 409 full-text articles reviewed, and 79 eligible studies (1,377,466 persons) were included. Mean age was 51.47 years and body mass index 28.90 kg/m2. Baseline comorbidities included metabolic syndrome (41.73%), cardiovascular disease (CVD) (16.83%), cirrhosis (21.97%), and nonalcoholic steatohepatitis (NASH) (58.85%). Incidence rate per 1,000 person-years for mortality included: all-cause (14.6), CVD-related (4.53), non-liver cancer-related (4.53), and liver-related (3.10). Incidence for liver-related events included overall (24.3), fibrosis progression (49.0), cirrhosis (10.9), liver transplant (12.0), and hepatocellular carcinoma (HCC) (3.39). Incidence for non-liver events included metabolic syndrome (25.4), hypertension (25.8), dyslipidemia (26.4), diabetes (19.0), CVD (24.77), renal impairment (30.3), depression/anxiety (29.1), and non-liver cancer (10.5). Biopsy-proven NASH had higher incidence of HCC (P=0.043) compared to non-NASH. Higher rates of CVD and mortality were observed in North America and Europe, hypertension and non-liver cancer in North America, and HCC in Western Pacific/Southeast Asia (P<0.05). No significant differences were observed by sex. Time-period analyses showed decreasing rates of cardiovascular and non-liver cancer mortality and increasing rates of decompensated cirrhosis (P<0.05). Conclusions: People with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.
참고문헌 (36)
- Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
- Le MH, "2019 Global NAFLD prevalence : A systematic review and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2809~2817 (2022)
- Targher G, "Non-alcoholic fatty liver disease : a multisystem disease requiring a multidisciplinary and holistic approach", Lancet Gastroenterol Hepatol, 6, pp.578~588 (2021)
- Allen AM, "Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death : A 20 year-community study", Hepatology, 67, pp.1726~1736 (2018)
- Le MH, "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States", PLoS One, 12, pp.e0173499~ (2017)
- Ong JP, "Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease", J Hepatol, 49, pp.608~612 (2008)
- Paik JM, "Changes in the global burden of chronic liver diseases from 2012 to 2017 : The growing impact of NAFLD", Hepatology, 72, pp.1605~1616 (2020)
- Gonzalez-Chagolla A, "Cirrhosis etiology trends in developing countries : Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico", Lancet Reg Health Am, 7, pp.100151~ (2021)
- Younossi ZM, "Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States", Clin Gastroenterol Hepatol, 19, pp.580~589 (2021)
- Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755 (2019)
- Dyson J, "Hepatocellular cancer : the impact of obesity, type 2 diabetes and a multidisciplinary team", J Hepatol, 60, pp.110~117 (2014)
- Pais R, "Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period", Aliment Pharmacol Ther, 46, pp.856~863 (2017)
- Younossi ZM, "Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U. S", Diabetes Care, 43, pp.283~289 (2020)
- Younossi ZM, "The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe", Hepatology, 64, pp.1577~1586 (2016)
- Le MH, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clin Mol Hepatol, 28, pp.841~850 (2022)
- "World Obesity Atlas 2023"[URL]
- Younossi ZM, "Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis : the value proposition", Hepatology, 68, pp.2405~2412 (2018)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
- Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol, 80, pp.e54~e56 (2024)
- Lee BP, "National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature", Hepatology, 79, pp.666~673 (2024)
- Xiao J, "Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD-An umbrella overview of systematic review of meta-analysis", J Clin Exp Hepatol, 13, pp.656~665 (2023)
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- Ekstedt M, "Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
- Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : A systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
- Mantovani A, "Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events : an updated systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.903~913 (2021)
- Byrne CD, "NAFLD as a driver of chronic kidney disease", J Hepatol, 72, pp.785~801 (2020)
- Roderburg C, "Non-alcoholic fatty liver disease(NAFLD)is associated with an increased incidence of chronic kidney disease(CKD)", Eur J Med Res, 28, pp.153~ (2023)
- Mantovani A, "Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers : a meta-analysis of observational cohort studies", Gut, 71, pp.778~788 (2022)
- Golabi P, "Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease(NAFLD)", Medicine(Baltimore), 97, pp.e0214~ (2018)
- Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
- Bianco C, "Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores", J Hepatol, 74, pp.775~782 (2021)
- Yip TC, "Asian perspective on NAFLD-associated HCC", J Hepatol, 76, pp.726~734 (2022)
- Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
- Mishra S, "Work-up for Incidentally Detected NAFLD : How Far is It Worth?", Euroasian J Hepatogastroenterol, 12(Suppl 1), pp.S26~S36 (2022)
- Younossi ZM, "The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH) : a systematic review", Hepatology, 77, pp.1335~1347 (2023)
- Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)